In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...